Alyeska Investment Group L.P. Invests $4.63 Million in Atyr PHARMA INC (NASDAQ:ATYR)

Alyeska Investment Group L.P. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,278,441 shares of the company's stock, valued at approximately $4,628,000. Alyeska Investment Group L.P. owned 1.52% of Atyr PHARMA as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Alterna Wealth Management Inc. bought a new position in shares of Atyr PHARMA during the fourth quarter worth about $36,000. Victory Capital Management Inc. acquired a new position in shares of Atyr PHARMA in the 4th quarter worth approximately $37,000. Raymond James Financial Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at $39,000. XTX Topco Ltd acquired a new stake in shares of Atyr PHARMA during the fourth quarter worth $40,000. Finally, Boothbay Fund Management LLC bought a new position in Atyr PHARMA during the fourth quarter worth $53,000. 61.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ATYR shares. Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday, February 18th. Cantor Fitzgerald began coverage on Atyr PHARMA in a research note on Monday, January 6th. They set an "overweight" rating for the company. Leerink Partners started coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Atyr PHARMA in a research report on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $18.60.

Atyr PHARMA Stock Down 0.6 %

Shares of NASDAQ:ATYR opened at $3.58 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The business's 50 day simple moving average is $3.29 and its two-hundred day simple moving average is $3.41. The firm has a market cap of $318.12 million, a P/E ratio of -3.81 and a beta of 0.79.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. As a group, research analysts forecast that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Want to see what other hedge funds are holding ATYR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atyr PHARMA INC (NASDAQ:ATYR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.